TPMT基因型正常的炎症性肠病患者中硫嘌呤诱导的白细胞减少和感染的危险因素
多因素分析显示,与硫唑嘌呤相比,使用巯嘌呤与白细胞减少相关(HR 2.61),基线白细胞计数较高具有保护作用(HR 0.80);感染的危险因素为年龄较大(每10年HR 2.07)和联用生物制剂(HR 2.15)。
要点
- 无TPMT变异的炎症性肠病患者中,使用巯嘌呤较硫唑嘌呤增加白细胞减少风险(HR 2.61)。
- 基线白细胞计数较高对硫嘌呤诱导的白细胞减少具有保护作用(HR 0.80)。
- 年龄较大和联用生物制剂是感染的危险因素(HR分别为2.07和2.15)。
核心结论
- 无TPMT变异的炎症性肠病患者中,低基线白细胞计数和使用巯嘌呤(因剂量相对较高)是硫嘌呤诱导的白细胞减少的危险因素。
研究设计与样本
- 采用单因素和多因素Cox比例风险模型识别白细胞减少和感染的危险因素。
主要发现
- 多因素分析显示,与硫唑嘌呤相比,使用巯嘌呤与白细胞减少相关(HR 2.61 [95% CI 1.39-4.88;P < .01])。
- 基线白细胞计数较高具有保护作用(HR 0.80 [95% CI 0.71-0.89;P < .01])。
- 感染的危险因素包括年龄较大(每10年HR 2.07 [95% CI 1.18-3.63;P = .01])和联用生物制剂(HR 2.15 [95% CI 1.14-4.07;P = .02])。
关键数值与推荐
- 白细胞减少定义为白细胞计数 <3.0 × 10^9/L。
- 感染根据常见不良事件评价标准(CTCAE)分类。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Leucopenia is a common side effect in patients treated with thiopurines. Variants in the thiopurine S-methyltransferase (TPMT) gene are the best-known risk factor, but only explain up to 25% of leucopenia cases. AIM: To identify the clinical risk factors for thiopurine-induced leucopenia in patients without a common TPMT variant, and explore if these patients are at increased risk for infections. METHODS: Post hoc analysis of the Thiopurine response Optimisation by Pharmacogenetic testing in Inflammatory bowel disease Clinics (TOPIC) trial. For this analysis, patients without a variant in TPMT (*2, *3A or*3C) were included. Uni- and multivariate Cox-proportional hazard models were used to identify risk factors for leucopenia and infections. Leucopenia was defined as a white blood cell (WBC) count <3.0 × 109 /L and infections were classified according to the Common Terminology Criteria for Adverse Events. RESULTS: Sixty hundred and ninety-five patients (90.6%) included in the TOPIC-trial had no variant in TPMT, of which 45 (6.5%) developed leucopenia. Median time to leucopenia was 56 (29-112) days. Multivariate analysis showed that use of mercaptopurine compared to azathioprine was associated with leucopenia (hazard ratio [HR] 2.61 [95% CIs, 1.39-4.88; P < .01]) and a higher baseline WBC count was protective (HR 0.80 [95% CIs, 0.71-0.89; P < .01]). Risk factors for infections were older age (per 10 year; HR 2.07 [95% CIs, 1.18-3.63; P = .01]) and concomitant use of biologic drugs (HR 2.15 [95% CIs, 1.14-4.07; P = .02]). CONCLUSIONS: Low baseline WBC count and mercaptopurine, due to a relatively higher dose, were risk factors for thiopurine-induced leucopenia in patients without a TPMT variant.
引用
- Broekman MMTJ, Coenen MJH, Wanten GJ, et al. Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype. Aliment Pharmacol Ther. 2017. PMID: 28914446. doi:10.1111/apt.14323
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。